Where cell culture fermentation and microbial fermentation part company as manufacturing routes: what a fermentation bioreactor, a cell bioreactor, a cell culture bioreactor, a bioreactor for cell culture and a bioreactor for mammalian cell culture each demand in oxygen transfer and heat removal, and how much of a bioreactor cell culture process is decided by the bioreactor vessel and its oxygen cell measurement rather than by the medium, where a batch route, a continuous bioreactor, an automated bioreactor, a benchtop bioreactor and a stainless steel bioreactor sit against each other, why continuous manufacturing changes control and release rather than only throughput, what monoclonal antibodies manufacturing has standardised that biosimilar manufacturing then has to match rather than merely equal, how biologics process development decides which of those is even possible, and what well characterized biologics means for the analytical package a programme has to build

Choosing the route and the control strategy

1. Let the molecule choose the host. Proteins requiring human like glycosylation, complex disulphide bonding or secretion of large multimers need mammalian culture. Simpler proteins that fold without those features are faster and much cheaper microbially, and the decision is effectively irreversible.
2. Size oxygen transfer and heat removal for microbial routes. Dense cultures consume oxygen and generate heat at rates that limit scale before volume does. Those two utilities, not vessel size, are what determine whether a process transfers to a given plant.
3. Decide batch, fed batch or continuous with the analytics in mind. Continuous operation raises volumetric productivity and shortens residence time, and it changes what a batch is, how release works and what in process control has to detect. It is a control strategy decision as much as an engineering one.
4. Build comparability into a biosimilar programme from the start. A biosimilar has to match a reference product across an extensive analytical panel, which means the process is developed toward a target rather than toward a specification. That inverts the usual development sequence.
5. Develop the analytical package alongside the process. Identity, purity, charge and size variants, glycan profile, potency and the impurity panel. Characterisation is what turns a product into a well characterised one, and it takes longer than the process work.
6. Fix the process before it becomes expensive to change. Culture mode, host, purification sequence and critical parameters should be settled before clinical material is made, because changing any of them afterwards triggers a comparability exercise.

Utilities decide where a process can run

Two plants with the same nominal vessel volume can differ enormously in what they can actually run, because oxygen transfer capability, cooling and mixing differ. A process characterised only by volume and duration does not tell a receiving site whether it can be run there.

Describe the process in terms of the demands it makes rather than the equipment it was developed on. That is what makes a transfer possible.

Comparability is the recurring cost

Every meaningful change to a biologics process, whether route, scale, site or raw material, raises the question of whether the product is the same. Answering that question requires an analytical package and often a study.

The way to keep that cost down is to make the changes early, while there is little clinical material to compare against, and to fix the process before it becomes the thing being defended.

Common questions

When is microbial expression not an option?

When the product needs human like glycosylation, when it is large and multi domain, or when correct disulphide formation cannot be achieved. Those constraints rule out the cheaper route regardless of economics.

What actually limits microbial scale up?

Oxygen transfer and heat removal, and mixing time in large vessels. Volume is rarely the binding constraint, which is why a process that works in a small fermenter can fail in a plant with different utilities.

Does continuous processing reduce cost?

It can raise productivity per unit volume substantially and reduce facility footprint, while adding control complexity and changing how batches are defined and released. The saving is real and it is not automatic.

What makes a biologic well characterised?

An analytical package extensive enough that product quality attributes are understood and controlled, rather than inferred from process consistency. It is a description of the evidence, not of the molecule.

Browse by service class

• Compare Gene synthesis on advertised prices